Abstract
Lung cancer has become the primary cause of cancer-related deaths because of its high recurrence rate, ability to metastasise easily, and propensity to develop drug resistance. The wide-ranging heterogeneity of lung cancer subtypes increases the complexity of developing effective therapeutic interventions. Therefore, personalised diagnostic and treatment strategies are required to guide clinical practice. The advent of innovative three-dimensional (3D) culture systems such as organoid and organ-on-a-chip models provides opportunities to address these challenges and revolutionise lung cancer research and drug evaluation. In this review, we introduce the advancements in lung-related 3D culture systems, with a particular focus on lung organoids and lung-on-a-chip, and their latest contributions to lung cancer research and drug evaluation. These developments include various aspects, from authentic simulations and mechanistic enquiries into lung cancer to assessing chemotherapeutic agents and targeted therapeutic interventions. The new 3D culture system can mimic the pathological and physiological microenvironment of the lung, enabling it to supplement or replace existing two-dimensional culture models and animal experimental models and realize the potential for personalised lung cancer treatment.
1 Introduction
Lung cancer is a common cancer worldwide and the leading cause of cancer-related deaths. In 2020 alone, over 2.2 million new cases and nearly 1.8 million deaths were attributed to lung cancer (). In particular, lung cancer is complex and diverse with different subtypes, including small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), which can also be divided into adenocarcinoma, squamous cell carcinoma (SCC), and large cell neuroendocrine carcinoma (LCNEC). Advancements in comprehensive treatments, including surgery, radiotherapy, chemotherapy, gene-targeted therapy, and immunotherapy, have improved therapeutic outcomes and prolonged survival in patients with lung cancer. However, various challenges remain, such as tumour recurrence, invasive metastasis, and drug resistance. Therefore, personalised diagnostic and therapeutic strategies are required, and more accurate lung cancer models must be developed.
Platforms for studying lung cancer and drug evaluation can be divided into in vitro and in vivo models, including two-dimensional (2D) cell culture, animal models, and three-dimensional (3D) culture systems such as organoids and organ-on-a-chip. In vitro 2D cell cultures are typically used models for studying tissue pathophysiology and drug response (); however, owing to the limitations of cell culture conditions, they cannot fully simulate the specificity of human tissue structure, mechanics, and function (). Animal models have also been used to simulate human physiological and pathological microenvironments for disease research, preclinical drug development, and screening. However, because of the inevitable differences in physiological structure, tissue and organ function, life maintenance, and other aspects between animals and humans, animal models cannot accurately simulate the physiological and pathological environment of the human body (; ); thus, experimental results from animals cannot be used to predict human drug reactions. Moreover, recent biological therapies using monoclonal antibodies and gene vectors require experimental models that include specific human target molecules or conformations that animal models cannot provide (). In addition, animal experiments require longer model manufacturing times, lower stability, and ethical considerations (). Therefore, owing to the limitations of 2D cell cultures and animal models, efficient new approaches are required to develop advanced 3D models for disease modelling, drug development, and screening. At the same time, compared to general 3D models, the construction of lung or lung tumour 3D models is more challenging. Because the lungs, as the respiratory organs of the human body, have a special series of biological features and unique respiratory membranes. Its features include biophysical and biochemical factors, such as special gases, fluids, soluble cytokines, air-liquid interfaces and respiratory movements, which are clearly different from other 3D models. Therefore, the study of advanced 3D lung culture system models, especially lung organoids and lung-on-a-chip, requires the integration of multiple fields such as materials science, tissue engineering, and biomedicine.
In recent years, with the continuous progress in microfabrication and tissue engineering technologies, the construction of advanced 3D culture systems has enabled the establishment of biomimetic 3D human tissue or organ models, which may solve the problems prevalent in existing 2D cell culture and animal models (; Tian et al., 2023). Moreover, these models can more accurately simulate lung cancer and evaluate drug efficacy (). Among them, organoids and organ-on-a-chip systems belong to advanced 3D culture systems. Organoids are complex multicellular clusters generated during the in vitro culture of stem cells related to a specific organ. The 3D microenvironment of the model framework comprises both a simulation of the corresponding disease environment to form a complex tissue structure and a simplified version of the organ. In contrast, organ-on-a-chip is a biomimetic device mimicking the main functions of human organs using microfluidic chips. These devices have microscale gas or fluid channels that can simulate the tissue microenvironment and blood circulation system, constructing certain tissue–tissue interfaces and organ–organ interfaces, thereby simulating microenvironments, complex structures, and biophysical factors of human organs. Consequently, they can address the limitations in animal experiments, such as species differences, long experimental cycles, high costs, and ethical concerns (; ). Figure 1 shows a comparison between the traditional 2D cell cultures, animal models, and 3D culture systems regarding human cells, tissue architecture, real-time monitoring, physiological biomechanics, low cost, and high throughput. Among them, lung organoids and lung-on-a-chip have significant advantages in human cell culture and real-time monitoring compared to animal models. In particular, compared with 2D cell cultures, they have significant advantages regarding tissue architecture and physiological biomechanics. More importantly, the organ-on-a-chip can shorten the research process by enhancing the stability of the culture system for drug development research, which in turn improves the performance of drug efficacy evaluation (). Studies have shown that the organ-on-a-chip significantly reduces R&D costs by approximately 25% of the total process, and can also bring additional benefits (). Both are acceptable regarding cost and throughput, providing a new strategy for solving the problems in current 2D cell cultures and animal models. In this review, we summarise novel lung-related 3D culture systems, including lung organoids and lung-on-a-chip. Moreover, we focus on the latest progress in lung cancer research and drug evaluation, including lung cancer simulation and mechanism research, chemotherapeutic drugs, and targeted drug evaluation. Novel 3D culture systems can mimic the pathological or physiological microenvironment of the lung, enabling it to supplement or replace existing 2D culture and animal experimental models, indicating its potential for personalised lung cancer treatment.
FIGURE 1
2 Lung organoids
Lung organoids can be developed using patient-derived tumour cells (PDCCs) or human embryonic stem cells (ESCs) along with key cytokines critical for lung development. These organoids aim to replicate the growth and differentiation of the lung in vitro, enabling a more precise examination of tumour growth mechanisms and evaluation of new anti-cancer medications (). Sources of lung organoid cells primarily comprise lung stem cells, lung mesenchymal stromal cells (MSCs) with differentiation potential, and PDCCs. Moreover, Pluripotent stem cells (PSCs) can be obtained from ESCs and induced pluripotent stem cells (iPSCs). Lung organoids were first developed in 1981 using ESCs (). In 1987, Zimmermann et al. cultured mouse foetal lung cells, resulting in a lung organoid with alveolar-like cavities and a basal lamina at the interface between the medium and air (Zimmermann, 1987). In 2010, Franzdottir et al. co-cultivated human bronchial cells with human umbilical vein endothelial cells (HUVECs) to form bronchioalveolar-like structures (). However, this 3D model suffers from the inability to fully represent the histologic differences that exist within the proximal and distal lung and airway epithelium, as well as the dependence on lung stem cells. In 2020, Meyer-Berg et al. created lung bud organoids (LBOs) for patients with certain lung genes using human ESCs and recombinant adeno-associated viruses (rAAV) (). In 2019, Miller et al. differentiated human pluripotent stem cells (hPSCs) into human lung bronchial and fine bronchial-like organoids in 2019 (). Moreover, iPSCs were prepared by , representing a milestone event and leading to new opportunities for stem cell research. In contrast to embryonic stem cells (ESCs), which are derived from ESCs, iPSCs can be generated by somatic gene reprogramming. This has expanded the sources of stem cells in lung organoids. In 2020, Leibel et al. produced a 3D multicellular organoid by inducing differentiation of human ESCs and iPSCs, including epithelial cells, MSCs, ciliated cells, and alveolar macrophages (). The process of organogenesis, which involves multiple cell screens and timing of cytokine additions, which can be combined with automated modes to obtain higher yields with fewer treatments.
From the perspective of disease models, researchers have primarily focused on constructing organoid models of and performing pharmacological research on five major diseases, including asthma, chronic obstructive pulmonary disease (COPD), fibrotic diseases, infections, and lung tumours. For example, Notch2 has been identified as a key regulatory factor promoting goblet epithelial hyperplasia (GCM) in the bronchial airway, which is also a leading cause of asthma and COPD. Therefore, simulation of Notch2 expression in bronchial cells may explain the mechanism of disease occurrence. In 2015, Danahay introduced an organoid model with alveolar epithelial cells that could simulate the proliferation of goblet cells and mucus increase in asthma (). It fully reduced the 3D structure of the inflammatory changes in multilayer. including basal cell progenitors, goblet cells, and ciliated cells. In addition, Rao et al. used single-cell cloning technology to culture lung tissues from patients with COPD and studied the mechanisms of inflammation, fibrosis, excessive mucus secretion, and metaplastic epithelial lesions in 2020 (). Lung organoid models have also been used to study fibrotic diseases such as idiopathic pulmonary fibrosis (IPF). In 2017, Surolia et al. cultured resected tissues from patients with IPF to form 3D organoids (). Alternatively, Wilkinson et al. established an IPF-style model of progressive scar formation using embryonic lung fibroblasts or induced pluripotent stem cell-derived mesenchymal cells treated with transforming growth factor-β (TGF-β) (Wilkinson et al., 2017). Moreover, organoid models can be used to study various types of infection models by simulations, such as infection caused by Mycobacterium () and Streptococcus (). Virus-infected lung organoid models have recently attracted increasing attention. In 2019, Sachs et al. infected organoids containing the small airway epithelium with a respiratory syncytial virus to explore the effect of viruses on airway remodelling (). The outbreak of SARS-CoV-2 in 2020 resulted in several studies examining lung organoids infected with COVID-19. Han et al. used a lung organoid model of hPSCs to investigate the strong induction effects of SARS-CoV-2 infection on chemokines (). In recent years, with the improvement of the manufacturing technology of the models and further understanding of the growth factors required for tumour cells, the lung cancer organoid (LCO) model has been developed from foundation to maturity. Generally, the process of constructing an LCO involves the following steps: selecting appropriate samples from sources such as surgical resection specimens, pleural effusion, or sputum from patients, and seeding the cells into plates containing growth factors after washing, incubation, dissociation, labelling, magnetic separation, and other steps. Finally, the function and value of LCO were assessed by measuring the content of tumour markers and verifying the purity of the cells in the tumour organ. In 2018, Clevers et al. developed an early LCO model (), and in 2019, Kim et al. defined 80 cases of LCOs containing five types of lung cancer (). The milestone events in the development of lung organoids in recent years is shown in Figure 2.
FIGURE 2
3 Lung-on-a-chip
Organ-on-a-chip is a biomimetic device with microscale gas or fluid channels that can simulate tissue and blood circulation systems. Organs can build tissue-tissue interfaces and organ-organ interfaces, simulating the microenvironment, complex structure and biophysical factors of human organs. It is more accurate and realistic compared to the two-dimensional model, and it can solve the shortcomings of animal experiments, such as species differences, long cycle time, high cost, animal ethics and other issues (; ). This device is used as a model for evaluating drug toxicity and efficacy by constructing certain tissue-tissue interfaces and organ–organ interfaces to simulate the microenvironment, complex structure, and biophysical factors of human organs. As one of the earliest organ-on-a-chip systems proposed and developed, the lung-on-a-chip can be applied not only to model development and drug evaluation of pulmonary oedema, pulmonary thrombosis, viral infection, and other diseases (; ; ; ) but also to model building and drug evaluation of lung tumour (; Wilkinson et al., 2017).
Moreover, lung-on-a-chip can be used to culture normal human alveolar epithelial cells, HUVECs (), respiratory muscle tissue cells (), primary lung cancer cells (Xu et al., 2013), a single lung cancer cell line (), lung cancer fibroblast cell lines (Yang et al., 2018), and additional types of cellular components of the mixture on the microchip. Its main structure comprises upper and lower microfluidic channels. The upper microchannels can be used to culture alveolar epithelial cells, forming air–liquid interface to simulate alveoli by applying oxygen. The lower microchannels can be used to culture HUVECs and continuously perfuse culture fluid to simulate capillary channels and fluid shear stress. The middle of upper and lower microchannels sandwich a porous membrane to simulate alveolar septa. Side chambers exist on both sides of the lung-on-a-chip connected to two vacuum pumps; the porous film is regularly stretched by changing the pressure of the side chambers, which simulates the respiratory motion of the lungs (). Cellular components are placed into their respective channels and cultured in a continuously replenished 3D medium such that after a certain period, the cells form functional tissue units (Xu et al., 2013). The materials of lung-on-a-chip are the basis for their fabrication and application. Materials typically used include polydimethylsiloxane (PDMS), paper, poly lactic-co-glycolic acid (PLGA), and extracellular matrix (ECM). In 2010, Huh et al. established an original lung-on-a-chip model, which consisted of alveolar epithelial cells and HUVECs, reproducing the alveolar-capillary interface and the air-blood barrier (). In 2014, Sellgren et al. added lung fibroblasts to Huh’s lung-on-a-chip (). In the same year, McCain et al. created a lung organ-on-a-chip model containing human respiratory musculature (). The main advantages of PDMS are non-toxic, light-transmitting, chemically inert, easy to process, and inexpensive, being widely used in the fabrication of lung microarrays, and its main disadvantage is relatively hydrophobic (), which often requires the modification of a layer of biocompatible extracellular matrix or hydrogel material (). Another drawback is the high uptake rate of hydrophobic drugs (). In 2015, Stucki et al. used photolithography to create a lung-on-a-chip containing a stretched alveolar barrier to mimic the diaphragm during in-vivo respiratory movements (). In 2016, Ziaie et al. used parchment paper treated with a laser as a semi-permeable membrane to construct an air-liquid interface to culture monolayer lung epithelial cells (). There are drawbacks to this type of parchment paper, one of which is that it requires laser processing in order to form hydrophilic regions, and the other is that prolonged in vitro incubation can lead to a weakening of the wet and dry tensile strength, and may even disrupt the semipermeable membrane. In 2018, Hu et al. developed a thermoplastic model of a lung-on-a-chip that recapitulated the lung airway microenvironment and the interactions between smooth muscle cells, epithelial cells, and the supporting extracellular matrix (). In the same year, Gao et al. used PLGA nanofiber membranes for the first time with extremely thin thickness (approximately 3 μm) and improved biocompatibility and porosity as an intermediate porous film material (Yang et al., 2018). However, biophysical factors such as fluid shear and tensile stress cannot be simulated due to the lack of strength of the PLGA material. In 2019, Park et al. used 3D cellular bioprinting, mixed polycaprolactone, lung fibroblast bioink, endothelial cell bioink, and PDMS to construct a lung-on-a-chip platform (). Finally, in 2021, Guenat et al. used collagen and elastin to design a lung-on-a-chip with biogenic, stretchable, and degradable membranes mimicking arrays of tiny alveoli in vivo dimensions (Zamprogno et al., 2021). ECM membrane is better than PDMS in many ways, not absorbing hydrophobic drugs, biogenic, stretchable, and degradable, can be prepared very thin membranes (around 4 μm), but its degree of toughness is not sufficient.
Lung-on-a-chip is currently used for disease simulation in inflammation, pathogen infection, and lung tumors. In 2016, Benam et al. designed a small bronchial chip for simulating inflammatory responses in the small airways at the sub-organ level (). After that, researchers recognized that pathogens can affect the lung epithelial structure and function of lung-on-a-chip and gradually began to study models containing host-pathogenic microorganisms. These studied included lung-on-a-chip models containing Mycobacterium tuberculosis (), Staphylococcus aureus and influenza A virus co-infected pneumonia (), rhinovirus (), and virus analog poly (I: C) and SARS-CoV-2 pseudovirus (). In addition, constructing NSCLC models based on lung-on-a-chip has become a current hotspot. Researchers has used NSCLC models to study the development, metastasis, and drug resistance of lung cancer. We have also carried out some work. In 2022, we used NCI-H1650 cells, the primary human NSCLC, and HUVECs to construct a lung-on-a-chip platform for evaluating the response of lung cancer cells to epidermal growth factor receptor (EGFR)-targeted drugs (). The progress of important events in lung-on-a-chip in recent years is summarised in Figure 3.
FIGURE 3
4 Applications of lung organoids and lung-on-a-chip
To further elucidate the advantages of advanced lung organoids and lung-on-a-chip over traditional systems, some representative images of lung organoids and lung-on-a-chip in Figure 4 and Figure 5 highlight the unique features of 3D systems that are not feasible in animal models or 2D cell cultures. Based on the above lung organoids and lung-on-a-chip, we categorised the principal lung organoids and lung-on-a-chip based on their various features to simulate lung cancer in situ and metastatic lung cancer, study the mechanisms of lung cancer development, and evaluate drug treatments, as shown in Tables 1, 2.
FIGURE 4
FIGURE 5
TABLE 1
| Organoids | Cell types | Features | Mechanism | Drug testing | References |
|---|---|---|---|---|---|
| LCOs | Adenocarcinoma | Derived from primary lung cancer tissues and paired non-neoplastic airway tissues | — | Olaparib | |
| SCC | Own a greater long-term expansion potential | Erlotinib | |||
| ASC | Maintain histological and genetic characteristics | Crizotinib | |||
| LCNEC | |||||
| SCLC | |||||
| LCOs | Cells derived from SCLC patients | A amicrophysiological system | — | Cisplatin | |
| Enabled LCO culturing | Etoposide | ||||
| Finished drug sensitivity tests | |||||
| AOs | NSCLC | Human airway organoids from broncho-alveolar | The dramatic causes of RSV infection and the neutrophil–epithelium interaction in epithelial airway organoids | Paclitaxel | |
| CF cell | Modeled RSV infections | Methotrexate | |||
| Presented the direct effects of the viral protein NS2 | Crizotinib cisplatin | ||||
| LUAD organoids | PC-9 cancer cell | High cultivation success rate | Examined the effect of podoplanin (+) CAFs on the proliferation of cancer cells in the hybrid cancer organoids | — | |
| CAFs | Co-cultured the generation of hybrid cancer organoids | ||||
| Contains both cancer cells and podoplanin (+) CAFs | |||||
| LUAD and LUSC organoids | ASC | Cultured short-term and long-term organoids | — | Trametinib | |
| Preserve the mutation and copy number landscape | Selumetinib | ||||
| Combination therapy in NSCLC organoids | BGJ398+ | ||||
| Trametinib | |||||
| Combination | |||||
| LCOs | NCI-H460 | Cultured the cisplatin-resistant lung cancer organoids | HF induced G0/G1 phase arrest and apoptosis | HF, cisplatin | |
| NCI-H1299 | Evaluated the combination of cisplatin and HF | HF affected PI3K/AKT and MAPK signaling pathways | |||
| AT2 organoid | AT2 cell prominent cell of origin for LUAD | Organoid models of KRAS, BRAF, and ALK mutant | Chromosomal inversion leads to an oncogenic fusion between Eml4 and Alk using CRISPR/Cas9 technologies | — | |
| Cultured cell lines in F7 NHCS and growth factor-depleted media | |||||
| Tracked tumor-immune interactions in transplanted antigen-expressing organoids | |||||
| LCOs | Adenocarcinoma | Provided a personalized platform for the treatment of patients with unknown lung cancer | Osimertinib, BLU-667, and the combination of three groups showed great differences in proteomic profiles which indicated the mechanisms of drug resistance | Osimertinib | Wang et al. (2023) |
| SCC | Tested both targeted therapy and chemotherapy | Nabpaclitaxel | |||
| SCLC | Pemetrexed | ||||
| ASC pulmonary sarcomatous carcinoma | Carboplatin etoposide cisplatin | ||||
| PDOs | PDCC isolated from the malignant pleural effusion | Provided a model system that enables intimate investigation of the behaviors of cancer cells in the body | PDSs contributed to the enhancement of TGF-β to induce EMT, while PDOs attenuated it | — | |
| Compared the PDSs and PDO in both the interaction to the immune systems and to the stroma | |||||
| LCOs | LUAD | Used genetic engineering to make the induction of Wnt independency by EGFR/Ras alterations | Wnt-dependent and –independent phenotypes in lung adenocarcinoma are defined by NKX2-1 expression | Porcupine inhibitor (C59) | |
| LUSC | Introduced sgRNA targeting NKX2-1 into three lines of NKX2-1+ WRi LUAD organoids | Loss of the NKX2-1 sensitizes human lung adenocarcinomas to Wnt-targeting therapy | |||
| SCLC | Used targeting Wnt signaling for the treatment of LUAD | ||||
| LCNEC |
Lung cancer research utilizing lung organoid models.
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; SCC, squamous cell carcinoma; ASCs, adenosquamous carcinoma cells; LCNEC, large cell neuroendocrine carcinoma; LCO, lung cancer organoid; AOs, airway organoids; RSV, respiratory syncytial virus; CF, cystic fibrosis; LUAD, lung adenocarcinoma; CAFs, cancer-associated fibroblasts; LUSC, lung squamous cell carcinoma; HF, halofuginone; AT2, alveolar type 2; PDOs, patient-derived oganoids.
TABLE 2
| Construction materials | Cell types | Features | Mechanism | Drug testing | References |
|---|---|---|---|---|---|
| ECM-coated membrane | Human adenocarcinoma cells, H1975 | Monitored the growth and invasion of the orthotopic lung cancer | The changes in signaling through EGFR- and MET protein kinase may cause resistance to therapy | Rociletinib | |
| Analysis the effects of mechanical breathing on cancer behaviors | |||||
| Analysis EGHR-TKI therapeutic responses to physical modulation | |||||
| PLGA electrospinning nanofiber membrane | Human NSCLS cell A549, HFL1, HUVECs | Co-culture of A549 cells and HFL1 cells in a microchip | IGF-1 secreted by HFL1 cells could maintain the tumor cells by activating the PI3K/Akt signal pathway, resulting in decreased sensitivity of the tumor cells to drugs | Gefitinib | Yang et al. (2018) |
| Prepared four kinds of PLGA nanofiber membranes | |||||
| Evaluation of EGFR-targeted anti-tumor drug | |||||
| PLGA and PDMS membrane | Adenocarcinoma cell lines NCI-H460, Large cell carcinoma NCI-H1650 | A novel poly PLGA nanofiber/PDMS microporous composite membrane | The mechanism of the resistance of NCI-H460 cells to gefitinib under normoxic and hypoxic conditions | Gefitinib | |
| EGFR-Targeted drug evaluation under normoxia and hypoxia conditions | |||||
| ECM membrane | Human NSCLS cell A549, HUVECs | Delivered miR-497-loaded exosomes to co-cultured A549 cells with HUVECs in a microfluidic 3D lung cancer model | MiRNA-497 can suppress the tumor growth and the expression of their associated genes, like YAP1, HDGF, CCNE1, and VEGF-A, and decrease the VEGF-A-mediated angiogenic sprouting | MiRNA-497 | |
| Investigated the anti-tumor and anti-angiogenic effects of miRNAs on NSCLCs | |||||
| Hydrogel | Human NSCLS cell A549 and hAM-MSCs | Developed A549 and hAM-MSCs cells spheroid in a compartmentalized microfluidic device | Reduced the viability and the proliferative capacity of cancer by expressing cell proliferation marker Ki-67 | A novel tryptophan-rich peptide P1, ACP | |
| Tested cytotoxic effects of ACP on tumor spheroids | |||||
| PDMS polydimethylsiloxane membrane | PC9-Br cell line | Established a model of lung cancer brain metastasis based on a newly microfluidic multi-organ chip | GSH metabolism and the overexpression of various GSH metabolism-related enzymes (GPX4, RRM2, GCLC, GPX1, GSTM4, GSTM1). ALDH1A1, ALDH3A1 upregulated in BM | Cisplatin | Xu et al. (2020) |
| HBE hPMEC | Revealed the protein expression profile of PC9-Br to drug resistance | Carboplatin | |||
| HFL1 | Compared the different protein expression profile of PC9-Br with parental PC9 | Pemetrexed | |||
| THP-1 | Gefitinib | ||||
| AZD3759 | |||||
| PDMS | A549 cell | Established an organ-level lung cancer and liver linkage model | HIF-1α pathway elevates EMT transcription factors (Snail 1 and Snail 2) | HIF-1α inhibitors (tirapazamine, SYP-5, and IDF-11774) | Zheng et al. (2021) |
| GelMA | HIF-1 cell line | Explored the gene expression of cancer related markers under the normoxic and hypoxic conditions | |||
| PMMA | |||||
| PDMS | A-549 cell | A novel microfluidic chip with a dynamic environment and strategically placed U-shaped wells | — | Paclitaxel | |
| Combinatory drug treatment in dynamic and static culture | Vinorelbine | ||||
| Etoposide | |||||
| PC membrane | NCI-H1650 | Developed a microporous membrane lung chip based on 3D printing manufacturing technology | — | Gefitinib | |
| Primary human lung cancer cells | Tested the effects of different EGFR-targeted drugs on NCI-H650 cells and primary lung cancer cells in 2D well plates and 3D lung chips | Afatinib | |||
| HUVECs | Osimertinib |
Lung cancer research utilizing Lung-on-a-chip models.
ECM-coated membrane, porous extracellular matrix-coated membrane; PLGA, poly lactic-co-glycolic acid; PDMS, nanofiber/polydimethylsiloxane; HBE, human bronchial epithelial cells; HFL1, human lung fibroblasts; THP-1, human mononuclear cells; hPMEC, human pulmonary microvascular endothelial cells; ACP, anticancer peptide; hAM-MSCs, human amniotic membrane mesenchymal stem cells; BM, brain metastases; GelMA, gelatin methacryloyl; PMMA, poly methyl methacrylate; PC, polycarbonate.
4.1 Lung cancer modelling via lung organoids and lung-on-a-chip
4.1.1 Lung cancer in situ
The most important role of advanced lung organoids and lung-on-a-chip in developing lung cancer models to simulate lung cancer in situ is to maintain the tumour tissue characteristics. In 2019, Kim et al. isolated tumour cells from patients to create organoids replicating various carcinoma types, including SCCs, adenocarcinoma, adenosquamous carcinoma cells (ASCs), SCLC, and LCNEC (). Subsequently, in 2020, Shi improved Clevers’ approach to achieve high success rates in developing short- and long-term organoid models of NSCLS (). Due to the limitations of their use of primary cancer cells, these LCOs are unable to mimic the diversity of genetic alterations. Therefore, the development of truly personalized lung cancer therapies requires further genome-specific modified cells to test drug therapies. In 2022, Naranjo developed an optimised murine lung alveolar type 2 (AT2) organoid platform that enabled realistic simulation of lung adenocarcinoma (LUAD) through multigenerational expansion (). In particular, Naranjo genetically engineered organoids through genetic manipulation of AT2 cells with mutational activation of Kras, Braf, or Alk, as well as binding to the Trp53 (which corresponds to TP53 in humans) locus. In 2023, Ebisudani established 43 lines of LCOs, comprising 21 LUAD, seven SCC, 12 SCLC, and three LCNEC types (). Currently, 13 patient-derived organoid (PDO) models have been registered in clinical trials (). The lung-on-a-chip can model various lung cancer types in situ, similar to lung organoids. However, because of the challenging and delayed development of long-term cell culture on microchip systems, researches currently focused on in situ SCC, adenocarcinoma, and LCNEC. Moreover, studies on ASCs and SCLC (Yang et al., 2018; ) are limited.
4.1.2 Metastatic lung cancer
In addition to the aforementioned organoid and organ-on-a-chip studies on lung cancer, investigators are conducting studies on lung cancer metastasis. In 2016, Xu et al. designed a multi-organ microarray containing three layers of chambers that mimicked the invasive microenvironment of lung cancer, which can further be used to assess the mechanism of epithelial–mesenchymal transition (EMT) in lung cancer cells invading distant tissues and organs, such as the brain, bone, and liver (Xu et al., 2016). However, this lung cancer metastasis model only theorizes the impact of invasion by measuring the abnormal rate of the expression of cytokines, such as CXCR4, RANKL, and AFP to show the impact of invasion, which does not comprehensively show the interaction between lung cancer metastasis and tissues. In 2019, Nakamura et al. used a 3D organoid model containing cancer-associated fibroblasts (CAFs) and cancer cells to study the role of tumour-promoting growth factor podoplanin (+) CAFs in the proliferation and metastasis of lung adenocarcinoma cells in lung organoids. In particular, the authors evaluated the MIB-1 of podoplanin (+) and podoplanin (−) CAFs cancer cells to assess their MIB-1 index (). In 2020, Xu et al. constructed a microarray model of lung cancer brain metastases (BM) to investigate the mechanism underlying BM resistance to chemotherapeutic drugs and EGFR-TKI (Xu et al., 2020). In 2021, Zheng et al. constructed a microarray model of lung cancer liver metastasis in hypoxic conditions, explored the effect of hypoxia on hypoxia-inducible factor 1α (HIF -1α), and evaluated the therapeutic effects of HIF-1α inhibitors, tirapam, SYP-5, and IDF-11774, on cancer invasion (Zheng et al., 2021). Metastasis models are frequently based on lung cancer in situ models, with the addition of models of other tissues outside the lung linked by inter-chip channels to simulate metastasis.
Lung organoids are suitable when the research purpose is to maintain the characteristics of the original tumour tissue as they can be easily used in tumour cells in situ for 3D culture and remodelling of the tumour microenvironment (TME), which is conducive to studying the mechanism of tumourigenesis and development. However, when the aim is to build a multicellular co-culture environment and observe the characteristics of tumour invasion and metastasis, lung-on-a-chips are more advantageous than lung organoids. With its unique microchannel characteristics, multiple cells can be easily co-cultured in a controlled way. Moreover, lung-on-a-chips can be used to observe tumour cells in real time, facilitated by a microscope, which enables obtaining information challenging to obtain by conventional methods.
4.2 Research on lung cancer related mechanisms via lung organoids and lung-on-a-chip
4.2.1 Oxygen content in lung cancer
Lungs facilitate the gas exchange between the body and the outside world. The presence or absence of respiration and the level of oxygen content are crucial factors affecting tumour growth, as well as the expression of characteristics. In general, irregular growth of the vascular distance between tumour cells during the metastasis development can lead to an oxygen-rich or oxygen-suppressed state in the tumour environment (). Hypoxia regulates the expression of molecules such as p53 (), pyruvate kinase type M2(PKM2) (), and HIF -1α () in tumour cells, thus altering the glycolytic metabolism of the tumour and the expression of proteins. Jing et al. demonstrated that hypoxia can affect TME, drug resistance, DNA damage, and autophagy, leading to malignancy related to tumourigenesis (). A similar situation was observed in lung tumours. In this regard, researchers studied lung organoids and lung-on-a-chip. In 2019, Marhuenda determined the expression levels of epithelial cell adhesion molecules (EpCAMs) in four major subtypes of lung cancer cells, H522, H1437, H1975, and H520, under different hypoxic conditions to evaluate the effects of hypoxia on the growth and invasiveness of different subtypes of lung cancer (). Jin et al., in 2019, conducted a similar study to assess whether netrin-1 regulates the migration and invasion of lung cancer cells under hypoxic conditions and explore the underlying mechanism (). Considering that the aeration of lung organoids is closely related to membrane permeability, in 2020, Li et al. created NCI-H460X cells and compared their sensitivity to gefitinib under normoxic and hypoxic conditions. They found that hypoxia induced drug resistance in NSCLC (). In 2021, Zheng et al. designed a microfluidic chip that could precisely control the concentration of dissolved oxygen and found that under normoxic or hypoxic conditions, the HIF-1α pathway increased EMT and contributed to the metastatic progression of lung cancer to the liver (Zheng et al., 2021). On the other hand, the rate of oxygen metabolism may also reflect the extent of tumor growth. Relatedly, Nashimoto et al. have pioneered the measurement of oxygen consumption in HFL1 spheroids to further infer the rate of oxygen metabolism and assess the effects of anticancer drugs ().
4.2.2 Cancer-associated fibroblasts (CAFs)
Fibroblasts in cancer tissues, also known as CAFs, are essential components of tumour stromal cells. Various studies have demonstrated that CAFs are involved in the formation of the TME by autocrine secretion of TGF-β and stromal cell-derived factor-1 (SDF-1) (), vascular endothelial growth factor A (VEGFA) (), platelet-derived growth factor PDGF (), fibroblast growth factor (FGF), and chemokine (C-C motif) ligand 2 (CCL2) (Tsuyada et al., 2012). These cytokines or autocrine bodies are involved in stromal cell-tumour cell interactions by regulating signalling pathways such as PDGF-PDGFR and SDF-1-CXCR 4; they play crucial roles in capillary proliferation, activation, and migration of tumour cells, drug resistance generation, and immune escape during tumourigenesis (). Similarly, novel 3D culture systems have achieved improved results in recreating CAFs in lung cancer microenvironments. In 2018, Yang et al. used co-cultured lung-on-a-chip models of A549 tumour cells and HFL1 to explore the effects of HFL1 on tumour cell metastasis and drug resistance (Yang et al., 2018). In 2019, Nakamura et al. used surgically resected lung adenocarcinoma specimens to culture a 3D organoid model of CAF-containing cancer cells. They verified the roles of tumour growth promoter CAFs and podoplanin positivity in promoting cancer cell proliferation and evaluated the MIB-1 index by comparing podoplanin (+) and podoplanin (−) cancer cells in both groups (). In 2020, Chen et al. produced a 3D organoid system of SCC, co-cultured CAFs with lung squamous carcinoma cell to study the effects of CAFs on alveolar growth, morphology, and invasive destruction (). Microarray experiments also provide a more intuitive picture of the effects of fibroblasts on lung cancer. In 2023, Monleon-Guinot et al. used transmission electron microscopy to observe and compare the morphology of two groups of organoid models: A549 mixed cultures with CAFs and A549 mixed cultures with normal fibroblasts (NF). They found that CAFs promote the upregulation of the expression levels of EMT-related genes such as CDH1 and VIM (). These experimental results indicate that novel 3D models can demonstrate the complex interaction of cancer cell proliferation, invasion, and metastasis with CAFs (), providing a new platform for tumour mechanism research and drug evaluation.
4.2.3 Other cues
Other cues such as respiratory movements, infection, lung fibrosis, and oncogenes play essential roles in lung cancer development. In 2017, Hassell designed a classical two-channel microfluidic microarray experiment to explore the effect of physiological respiratory exercise on the growth and invasive patterns of lung cancer, H1975 (). Subsequently, in 2019, Sach et al. established a respiratory syncytial virus (RSV)-infected lung organoid model, exemplifying the process of recruiting neutrophils. Moreover, they explored the interaction mechanism between cystic fibrosis (CF), RSV infection, and cancer cells (). The lung-on-a-chip can also demonstrate the role of normal body components in lung cancer. In 2020, Xu et al. investigated the mechanism of action (GSH) and its related enzymes, such as GPX4 and RRM2, in a BM lung-on-a-chip (Xu et al., 2020). Moreover, Surina et al. developed models of PDOs and PDSs in lung cancer and compared the effect of TGF-β in the interaction mechanism between the EMT immunity system and the stroma in both models. More importantly, oncogene-specific genetic alterations can significantly affect the development of lung cancer models. In 2022, Naranjo et al. used genetic engineering techniques to obtain LCOs with specific Kras-, Trp53-deficient, and Eml53-Alk mutations, which significantly accelerated the study of the lung cancer genetic mechanisms (). In 2023, Ebisudani et al. used genetic engineering techniques to obtain NKX2-1-deficient lung adenocarcinoma carcinoid organs and discovered the mechanisms of resistance regulation in its downstream Wnt (). Currently, the combination of genetic engineering techniques and lung cancer model development is constantly evolving, facilitating the elucidation of the mechanisms of genetic factors in tumours.
The above experiments provide insights into the tumor development and resistance mechanisms based on different influencing factors. The insights enabled us to conclude that the two models, organoid and lung-on-a-chip, focus on the different tumour-influencing factors. The organoid models are more concerned with the structural study of biological tissues, such as the mechanism of CAFs and other important cellular components promoting tumour growth and invasion. In contrast, the lung-on-a-chip is focused on biological functions or physical factors affecting the cancer cells, such as the respiratory membrane of the lungs, air–liquid interface, gas shear, fluid shear, permeability of the membrane, and exchange of substances with the blood.
4.3 Anti-lung cancer drugs evaluation via lung organoids and lung-on-a-chip
4.3.1 Chemotherapy drugs
Chemotherapy is currently the most typical clinical treatment for lung cancer. Moreover, 3D models have been used since the early days to assess the efficacy of chemotherapeutic agents. In 2015, Ying et al. investigated the effects of CAFs and paclitaxel on Met/PI78K/AKT activation and GRP3 expression using a bilayer 3D perfusion cell culture microfluidic device integrated with a concentration gradient generator (Ying et al., 2015). In 2017, Zuchowska et al. first studied 3-aminolevulinic acid (ALA-PDT) in a 3D lung cancer model using a microfluidic system (Zuchowska et al., 2017). This method can determine the safe drug concentrations and parameters for PDT. In 2019, Jung tested the response to cisplatin in SCLC (). In 2021, Li and Zhang, using a lung organoid platform, determined that lung cancer cells were sensitised to cisplatin by inhibiting the PI3K/AKT and MAPK signalling pathways (). In addition, a combination of cisplatin and halofuginone (HF) showed that HF could sensitise lung organoids and lung cancer cells derived from patients resistant to cisplatin treatment, which may provide a new strategy to improve the prognosis of cisplatin-resistant lung cancer patients. Sankar et al., in 2021, screened the efficacy of three chemotherapeutic agents using a novel U-well 3D microfluidic chip to culture surgically resected lung cancer patient tissues. They determined that low-dose rhythmic chemotherapy could reduce the side effects of the drugs and provide better treatment outcomes ().
4.3.2 Targeted drugs
Targeted therapeutic agents are generally based on signalling pathways or physiological processes of specific tumour genes. Common targeted therapies for lung cancer include EGFR inhibitors, such as Erlotinib and Afatinib, and ALK inhibitors, such as Crizotinib and Alectinib. In 2017, Hassell et al. investigated the efficacy of osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib in a lung-on-a-chip (). In 2018, Yang et al. evaluated the EGFR-targeted antitumour drug gefitinib (Yang et al., 2018). Subsequently, in 2019, Kim evaluated the drug efficacy of PDO against olaparib, erlotinib, and crizotinib (). In 2020, by constructing long-term (greater than 3Â months, more than 10 generations), and short-term (less than 3Â months, less than 10 generations) NSCLC organoid models, Shi found that cancer organoids with breast cancer 2 gene, EGFR, and EGFR- and EGFR-mutation/MSC-epithelial-transformation (MET)-amplified mutations responded favourably to lapatinib, erlotinib, and crizotinib, respectively (). In the same year, Li et al. studied the role of hypoxia in inducing resistance to gefitinib using a lung-on-a-chip (). In 2022, our research team assessed the effects of the EGFR-TKIs gefitinib, osimertinib, and afatinib using a lung-on-a-chip (). Compared with general animal models, novel 3D models for the clinical assessment of targeted drugs eliminate specificity differences between species and predict drug responses in humans more precisely ().
4.3.3 Combined use of drugs
With the continuous updating of anti-lung cancer drugs, the demand for preclinical efficacy assessment combining anti-lung cancer therapies with different drugs has increased. In 2019, Sachs et al. used human airway organoids (AOs) to simulate viral infections and studied the combination of the conventional antitumour drugs paclitaxel and Nutlin-3a with crizotinib for lung cancer therapy (). However, there are drawbacks of fewer simulated immune cell types and less comprehensive simulation of infection in this experiment. The role of drugs combinations in the treatment of lung metastatic cancer has also been studied. In 2020, Xu et al. investigated the resistance mechanism of PC9-Br cells to chemotherapeutic agents and EGFR-TKI drugs in a BM lung-on-a-chip (Xu et al., 2020). In 2023, Wang HM conducted a LCO-based drug susceptibility test (LCO-DST) of osimertinib, paclitaxel, pemetrexed, carboplatin, etoposide, and cisplatin (Wang et al., 2023). Importantly, the study revealed the molecular mechanism of dual-target therapy by determining the proteomics of LCOs, enabling the prediction of individualised clinical responses of different patients to targeted therapy and chemotherapy.
4.3.4 Other therapies
In addition, lung organoids can be used to evaluate the effects of novel antitumour drugs. In 2020, Jeong et al. designed a microfluidic lung-on-a-chip to explore the antitumour and antiangiogenic effects of miR-497 in the TME of NSCLC (). The study revealed that exosome-mediated miRNAs could inhibit the growth, migration, and angiogenesis of targeted tumour cells in HUVECs, providing a new clinical therapeutic option for patients with lung cancer. In the same year, Dhiman et al. used a lung-on-a-chip model to explore the potential anti-cancer effects of the tryptophan-rich peptide P1 to provide a new strategy for lung cancer treatment (). In 2021, Zheng et al. explored the cancer development mechanism from lung to liver under normoxic or hypoxic conditions and drug testing of tirapamide, an HIF-1α inhibitor (Zheng et al., 2021). In 2023, Ebisudani tested C59, a novel porcupine inhibitor, for Wnt-targeted therapeutic efficacy in an NKX2-1-deficient lung adenocarcinoma chip (). These novel drug studies based on 3D culture systems provide new insights and directions for the future treatment of lung cancer.
5 Challenges and prospects
Lung cancer still represents a severe threat to human health despite its diagnosis and treatment progress. In particular, there is still a high risk of recurrence and a low 5-year survival rate after comprehensive treatment with surgical therapy, radiotherapy, chemotherapy, gene-targeted therapy, immunotherapy, and the implementation of various approaches. Therefore, the pathogenesis of lung cancer must be studied to develop new anti-lung cancer drugs. This review summarised various applications of advanced 3D culture systems for modelling, drug evaluation, and mechanistic lung cancer studies. However, with the continuous progress in tumour research, many researchers believe that a tumour is not just a single-organ lesion but also a systemic disease. The target organs for lung cancer metastasis not only involve the lungs but also multiple organs such as the brain, liver, adrenal glands, and bones. Thus, a single biomimetic lung-on-a-chip will not be able to simulate the entire tumour process in the human body. In addition, antitumour drugs may involve more complex pharmacokinetic reactions, such as drug absorption, metabolism, and damage to other organs. Therefore, disease and drug evaluation models are highly required. In this regard, the combination of organoids and organ-on-a-chip may represent a new direction for future research. The constantly proposed human-on-a-chip and organoid-on-a-chip is gradually developing, facilitating higher requirements for materials science, tissue engineering, artificial intelligence, etc. Although various challenges remain open, but more and more researchers are joining this field of research and believe that with the development of various technologies, such as micro/nanofabrication technology, intelligent materials, tissue/organ engineering, bioinformatics, etc., the Advanced 3D Culture Systems are expected to solve the current research bottlenecks. In conclusion, an increasing number of studies have shown that the use of bionic organoids and organ-on-a-chip are reliable microphysiological systems that can reproduce the in vivo microenvironment of tumours and can be used as supplements or alternatives to 2D cultures and animal experiments.
Statements
Author contributions
LZ: Conceptualization, Data curation, Formal Analysis, Writing–original draft. JZ: Conceptualization, Writing–original draft, Validation. QG: Writing–original draft, Formal Analysis, Resources. JK: Formal Analysis, Resources, Writing–original draft. DL: Writing–original draft, Data curation, Investigation. MW: Data curation, Investigation, Writing–original draft. YM: Writing–original draft, Formal Analysis. TZ: Writing–original draft, Data curation. XG: Supervision, Writing–review and editing. JT: Supervision, Writing–review and editing, Funding acquisition.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Shenzhen Hospital of Southern Medical University, Research Promotion Funds for the Key Discipline Construction Program (No. ZCXM2022XZ000705).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
BenamK. H.VillenaveR.LucchesiC.VaroneA.HubeauC.LeeH. H.et al (2016). Small airway-on-a-chip enables analysis of human lung inflammation and drug responses in vitro. Nat. Methods13 (2), 151–157. 10.1038/nmeth.3697
2
CaoT.ShaoC.YuX.XieR.YangC.SunY.et al (2022). Biomimetic Alveolus-on-a-Chip for SARS-CoV-2 infection recapitulation. Res. (Wash D C). 2022, 9819154.10.34133/2022/9819154
3
ChenS.GiannakouA.GolasJ.GelesK. G. (2020). Multidimensional coculture system to model lung squamous carcinoma progression. J. Vis. Exp.157. 10.3791/60644
4
DanahayH.PessottiA. D.CooteJ.MontgomeryB. E.XiaD.WilsonA.et al (2015). Notch2 is required for inflammatory cytokine-driven goblet cell metaplasia in the lung. Cell Rep.10 (2), 239–252. 10.1016/j.celrep.2014.12.017
5
Deinhardt-EmmerS.RennertK.SchickeE.CseresnyesZ.WindolphM.NietzscheS.et al (2020). Co-infection with Staphylococcus aureus after primary influenza virus infection leads to damage of the endothelium in a human alveolus-on-a-chip model. Biofabrication12 (2), 025012. 10.1088/1758-5090/ab7073
6
DhimanN.ShagaghiN.BhaveM.SumerH.KingshottP.RathS. N. (2020). Selective cytotoxicity of a novel trp-rich peptide against lung tumor spheroids encapsulated inside a 3D microfluidic device. Adv. Biosyst.4 (4), e1900285. 10.1002/adbi.201900285
7
DijkstraK. K.CattaneoC. M.WeeberF.ChalabiM.van de HaarJ.FanchiL. F.et al (2018). Generation of Tumor-Reactive t cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell174 (6), 1586–1598.e12. 10.1016/j.cell.2018.07.009
8
EbisudaniT.HamamotoJ.TogasakiK.MitsuishiA.SugiharaK.ShinozakiT.et al (2023). Genotype-phenotype mapping of a patient-derived lung cancer organoid biobank identifies NKX2-1-defined Wnt dependency in lung adenocarcinoma. Cell Rep.42 (3), 112212. 10.1016/j.celrep.2023.112212
9
EvansM. J.KaufmanM. H. (1981). Establishment in culture of pluripotential cells from mouse embryos. Nature292 (5819), 154–156. 10.1038/292154a0
10
FranzdottirS. R.AxelssonI. T.ArasonA. J.BaldurssonO.GudjonssonT.MagnussonM. K. (2010). Airway branching morphogenesis in three dimensional culture. Respir. Res.11 (1), 162. 10.1186/1465-9921-11-162
11
FranzenN.van HartenW. H.RetelV. P.LoskillP.van den Eijnden-vanR. J.IjzermanM. (2019). Impact of organ-on-a-chip technology on pharmaceutical R&D costs. Drug Discov. Today24 (9), 1720–1724. 10.1016/j.drudis.2019.06.003
12
GazdarA. F.GaoB.MinnaJ. D. (2010). Lung cancer cell lines: useless artifacts or invaluable tools for medical science?Lung Cancer68 (3), 309–318. 10.1016/j.lungcan.2009.12.005
13
GilliesR. J. (2022). Cancer heterogeneity and metastasis: life at the edge. Clin. Exp. Metastasis39 (1), 15–19. 10.1007/s10585-021-10101-2
14
GuoX.OshimaH.KitmuraT.TaketoM. M.OshimaM. (2008). Stromal fibroblasts activated by tumor cells promote angiogenesis in mouse gastric cancer. J. Biol. Chem.283 (28), 19864–19871. 10.1074/jbc.M800798200
15
HanY.DuanX.YangL.Nilsson-PayantB. E.WangP.DuanF.et al (2021). Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. Nature589 (7841), 270–275. 10.1038/s41586-020-2901-9
16
HartungT. (2009). A toxicology for the 21st century--mapping the road ahead. Toxicol. Sci.109 (1), 18–23. 10.1093/toxsci/kfp059
17
HassellB. A.GoyalG.LeeE.Sontheimer-PhelpsA.LevyO.ChenC. S.et al (2017). Human organ chip models recapitulate orthotopic lung cancer growth, therapeutic responses, and tumor dormancy in vitro. Cell Rep.21 (2), 508–516. 10.1016/j.celrep.2017.09.043
18
HuhD.MatthewsB. D.MammotoA.Montoya-ZavalaM.HsinH. Y.IngberD. E. (2010). Reconstituting organ-level lung functions on a chip. Science328 (5986), 1662–1668. 10.1126/science.1188302
19
HumayunM.ChowC. W.YoungE. (2018). Microfluidic lung airway-on-a-chip with arrayable suspended gels for studying epithelial and smooth muscle cell interactions. Lab. Chip18 (9), 1298–1309. 10.1039/c7lc01357d
20
IakobachviliN.Leon-IcazaS. A.KnoopsK.SachsN.MazeresS.SimeoneR.et al (2022). Mycobacteria-host interactions in human bronchiolar airway organoids. Mol. Microbiol.117 (3), 682–692. 10.1111/mmi.14824
21
IngberD. E. (2022). Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat. Rev. Genet.23 (8), 467–491. 10.1038/s41576-022-00466-9
22
JeongK.YuY. J.YouJ. Y.RheeW. J.KimJ. A. (2020). Exosome-mediated microRNA-497 delivery for anti-cancer therapy in a microfluidic 3D lung cancer model. Lab. Chip20 (3), 548–557. 10.1039/c9lc00958b
23
JinX.LuanH.ChaiH.YanL.ZhangJ.WangQ.et al (2019). Netrin-1 interference potentiates epithelial-to-mesenchymal transition through the PI3K/AKT pathway under the hypoxic microenvironment conditions of non-small cell lung cancer. Int. J. Oncol.54 (4), 1457–1465. 10.3892/ijo.2019.4716
24
JingX.YangF.ShaoC.WeiK.XieM.ShenH.et al (2019). Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol. Cancer18 (1), 157. 10.1186/s12943-019-1089-9
25
JungD. J.ShinT. H.KimM.SungC. O.JangS. J.JeongG. S. (2019). A one-stop microfluidic-based lung cancer organoid culture platform for testing drug sensitivity. Lab a Chip19 (17), 2854–2865. 10.1039/C9LC00496C
26
KalluriR.ZeisbergM. (2006). Fibroblasts in cancer. Nat. Rev. Cancer6 (5), 392–401. 10.1038/nrc1877
27
KimM.MunH.SungC. O.ChoE. J.JeonH.ChunS.et al (2019). Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat. Commun.10 (1), 3991. 10.1038/s41467-019-11867-6
28
KojimaY.AcarA.EatonE. N.MellodyK. T.ScheelC.Ben-PorathI.et al (2010). Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc. Natl. Acad. Sci. U. S. A.107 (46), 20009–20014. 10.1073/pnas.1013805107
29
LeibelS. L.McVicarR. N.WinquistA. M.NilesW. D.SnyderE. Y. (2020). Generation of complete Multi-Cell type lung organoids from human embryonic and Patient-Specific induced pluripotent stem cells for infectious disease modeling and therapeutics validation. Curr. Protoc. Stem Cell Biol.54 (1), e118. 10.1002/cpsc.118
30
LiF. J.SuroliaR.LiH.WangZ.KulkarniT.LiuG.et al (2017). Autoimmunity to vimentin is associated with outcomes of patients with idiopathic pulmonary fibrosis. J. Immunol.199 (5), 1596–1605. 10.4049/jimmunol.1700473
31
LiH.ZhangY.LanX.YuJ.YangC.SunZ.et al (2021). Halofuginone sensitizes lung cancer organoids to cisplatin via suppressing PI3K/AKT and MAPK signaling pathways. Front. Cell Dev. Biol.9, 773048. 10.3389/fcell.2021.773048
32
LiW.SunX.JiB.YangX.ZhouB.LuZ.et al (2020). PLGA Nanofiber/PDMS microporous composite Membrane-Sandwiched microchip for drug testing. Micromachines (Basel)11 (12), 1054. 10.3390/mi11121054
33
LiY.GaoX.NiC.ZhaoB.ChengX. (2023). The application of patient-derived organoid in the research of lung cancer. Cell Oncol. (Dordr)46 (3), 503–519. 10.1007/s13402-023-00771-3
34
LiuJ.ZhangC.HuW.FengZ. (2019). Tumor suppressor p53 and metabolism. J. Mol. Cell Biol.11 (4), 284–292. 10.1093/jmcb/mjy070
35
LuoW.HuH.ChangR.ZhongJ.KnabelM.O'MeallyR.et al (2011). Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell145 (5), 732–744. 10.1016/j.cell.2011.03.054
36
MarhuendaE.CampilloN.GabasaM.Martinez-GarciaM. A.Campos-RodriguezF.GozalD.et al (2019). Effects of sustained and intermittent hypoxia on human lung cancer cells. Am. J. Respir. Cell Mol. Biol.61 (4), 540–544. 10.1165/rcmb.2018-0412LE
37
McCainM. L.AgarwalA.NesmithH. W.NesmithA. P.ParkerK. K. (2014). Micromolded gelatin hydrogels for extended culture of engineered cardiac tissues. Biomaterials35 (21), 5462–5471. 10.1016/j.biomaterials.2014.03.052
38
Meyer-BergH.ZhouY. L.PilarD. L. M.ZambranoA.HydeS. C.GillD. R. (2020). Identification of AAV serotypes for lung gene therapy in human embryonic stem cell-derived lung organoids. Stem Cell Res. Ther.11 (1), 448. 10.1186/s13287-020-01950-x
39
MillerA. J.DyeB. R.Ferrer-TorresD.HillD. R.OvereemA. W.SheaL. D.et al (2019). Generation of lung organoids from human pluripotent stem cells in vitro. Nat. Protoc.14 (2), 518–540. 10.1038/s41596-018-0104-8
40
Monleon-GuinotI.MilianL.Martinez-VallejoP.Sancho-TelloM.Llop-MiguelM.GalbisJ. M.et al (2023). Morphological characterization of human lung cancer organoids cultured in type i collagen hydrogels: a histological approach. Int. J. Mol. Sci.24 (12), 10131. 10.3390/ijms241210131
41
NakamuraH.SuganoM.MiyashitaT.HashimotoH.OchiaiA.SuzukiK.et al (2019). Organoid culture containing cancer cells and stromal cells reveals that podoplanin-positive cancer-associated fibroblasts enhance proliferation of lung cancer cells. Lung Cancer134, 100–107. 10.1016/j.lungcan.2019.04.007
42
NaranjoS.CabanaC. M.LaFaveL. M.RomeroR.ShanahanS.BhutkarA.et al (2022). Modeling diverse genetic subtypes of lung adenocarcinoma with a next-generation alveolar type 2 organoid platform. Genes and Dev.36 (15-16), 936–949. 10.1101/gad.349659.122
43
NashimotoY.MukomotoR.ImaizumiT.TeraiT.ShishidoS.InoK.et al (2023). Electrochemical sensing of oxygen metabolism for a three-dimensional cultured model with biomimetic vascular flow. Biosens. Bioelectron.219, 114808. 10.1016/j.bios.2022.114808
44
NawrothJ. C.LucchesiC.ChengD.ShuklaA.NgyuenJ.ShroffT.et al (2020). A microengineered airway lung chip models key features of viral-induced exacerbation of asthma. Am. J. Respir. Cell Mol. Biol.63 (5), 591–600. 10.1165/rcmb.2020-0010MA
45
ParkJ. W.VahidiB.TaylorA. M.RheeS. W.JeonN. L. (2006). Microfluidic culture platform for neuroscience research. Nat. Protoc.1 (4), 2128–2136. 10.1038/nprot.2006.316
46
ParkJ. Y.RyuH.LeeB.HaD. H.AhnM.KimS.et al (2018). Development of a functional airway-on-a-chip by 3D cell printing. Biofabrication11 (1), 015002. 10.1088/1758-5090/aae545
47
PerelsonA. S.RibeiroR. M. (2018). Introduction to modeling viral infections and immunity. Immunol. Rev.285 (1), 5–8. 10.1111/imr.12700
48
PietrasK.PahlerJ.BergersG.HanahanD. (2008). Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med.5 (1), e19. 10.1371/journal.pmed.0050019
49
PolanskaU. M.OrimoA. (2013). Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J. Cell Physiol.228 (8), 1651–1657. 10.1002/jcp.24347
50
RahimiR.HtweS. S.OchoaM.DonaldsonA.ZiegerM.SoodR.et al (2016). A paper-based in vitro model for on-chip investigation of the human respiratory system. Lab. Chip16 (22), 4319–4325. 10.1039/c6lc00866f
51
RaoW.WangS.DulebaM.NiroulaS.GollerK.XieJ.et al (2020). Regenerative metaplastic clones in COPD lung drive inflammation and fibrosis. Cell181 (4), 848–864.e18. 10.1016/j.cell.2020.03.047
52
SachsN.PapaspyropoulosA.Zomer-vanO. D.HeoI.BottingerL.KlayD.et al (2019). Long-term expanding human airway organoids for disease modeling. EMBO J.38 (4), e100300. 10.15252/embj.2018100300
53
SankarS.MehtaV.RaviS.SharmaC. S.RathS. N. (2021). A novel design of microfluidic platform for metronomic combinatorial chemotherapy drug screening based on 3D tumor spheroid model. Biomed. Microdevices23 (4), 50. 10.1007/s10544-021-00593-w
54
SellgrenK. L.ButalaE. J.GilmourB. P.RandellS. H.GregoS. (2014). A biomimetic multicellular model of the airways using primary human cells. Lab. Chip14 (17), 3349–3358. 10.1039/c4lc00552j
55
SempereJ.LlamosiM.LopezR. B.DelR. I.Perez-GarciaC.LagoD.et al (2022). Effect of pneumococcal conjugate vaccines and SARS-CoV-2 on antimicrobial resistance and the emergence of Streptococcus pneumoniae serotypes with reduced susceptibility in Spain, 2004-20: a national surveillance study. Lancet Microbe3 (10), e744–e752. 10.1016/S2666-5247(22)00127-6
56
ShiR.RadulovichN.NgC.LiuN.NotsudaH.CabaneroM.et al (2020). Organoid cultures as preclinical models of non–small cell lung cancer. Clin. Cancer Res.26 (5), 1162–1174. 10.1158/1078-0432.CCR-19-1376
57
ShirureV. S.GeorgeS. C. (2017). Design considerations to minimize the impact of drug absorption in polymer-based organ-on-a-chip platforms. Lab. Chip17 (4), 681–690. 10.1039/c6lc01401a
58
SnoeckH. W. (2015). Modeling human lung development and disease using pluripotent stem cells. Development142 (1), 13–16. 10.1242/dev.115469
59
StrzyzP. (2016). Cancer biology: hypoxia as an off switch for gene expression. Nat. Rev. Mol. Cell Biol.17 (10), 610. 10.1038/nrm.2016.119
60
StuckiA. O.StuckiJ. D.HallS. R.FelderM.MermoudY.SchmidR. A.et al (2015). A lung-on-a-chip array with an integrated bio-inspired respiration mechanism. Lab. Chip15 (5), 1302–1310. 10.1039/c4lc01252f
61
SugayaM.TakenoyamaM.OsakiT.YasudaM.NagashimaA.SugioK.et al (2002). Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. Chest122 (1), 282–288. 10.1378/chest.122.1.282
62
SungH.FerlayJ.SiegelR. L.LaversanneM.SoerjomataramI.JemalA.et al (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71 (3), 209–249. 10.3322/caac.21660
63
SurinaTanggisSuzukiT.HisataS.FujitaK.FujiwaraS.et al (2023). Patient-derived spheroids and patient-derived organoids simulate evolutions of lung cancer. Heliyon9 (3), e13829. 10.1016/j.heliyon.2023.e13829
64
TakahashiK.YamanakaS. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell126 (4), 663–676. 10.1016/j.cell.2006.07.024
65
TanJ.GuoQ.TianL.PeiZ.LiD.WuM.et al (2023). Biomimetic lung-on-a-chip to model virus infection and drug evaluation. Eur. J. Pharm. Sci.180, 106329. 10.1016/j.ejps.2022.106329
66
TanJ.SunX.ZhangJ.LiH.KuangJ.XuL.et al (2022). Exploratory evaluation of EGFR-Targeted Anti-Tumor drugs for lung cancer based on Lung-on-a-Chip. Biosens. (Basel)12 (8), 618. 10.3390/bios12080618
67
TaylorA. M.Blurton-JonesM.RheeS. W.CribbsD. H.CotmanC. W.JeonN. L. (2005). A microfluidic culture platform for CNS axonal injury, regeneration and transport. Nat. Methods2 (8), 599–605. 10.1038/nmeth777
68
ThackerV. V.DharN.SharmaK.BarrileR.KaralisK.McKinneyJ. D. (2020). A lung-on-chip model of early Mycobacterium tuberculosis infection reveals an essential role for alveolar epithelial cells in controlling bacterial growth. Elife9, e59961. 10.7554/eLife.59961
69
TianL.ShiJ.LiW.ZhangY.GaoX. (2023). Hollow microfiber Assembly-Based endocrine Pancreas-on-a-Chip for sugar substitute evaluation. Adv. Healthc. Mater, e2302104. 10.1002/adhm.202302104
70
TsuyadaA.ChowA.WuJ.SomloG.ChuP.LoeraS.et al (2012). CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res.72 (11), 2768–2779. 10.1158/0008-5472.CAN-11-3567
71
WangH.ZhangC.PengK.ChenZ.SuJ.LiY.et al (2023). Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: a real-world study. Cell Rep. Med.4 (2), 100911. 10.1016/j.xcrm.2022.100911
72
WilkinsonD. C.Alva-OrnelasJ. A.SucreJ. M.VijayarajP.DurraA.RichardsonW.et al (2017). Development of a Three-Dimensional bioengineering technology to generate lung tissue for personalized disease modeling. Stem Cells Transl. Med.6 (2), 622–633. 10.5966/sctm.2016-0192
73
XuM.WangY.DuanW.XiaS.WeiS.LiuW.et al (2020). Proteomic reveals reasons for acquired drug resistance in lung cancer derived brain metastasis based on a newly established Multi-Organ microfluidic chip model. Front. Bioeng. Biotechnol.8, 612091. 10.3389/fbioe.2020.612091
74
XuZ.GaoY.HaoY.LiE.WangY.ZhangJ.et al (2013). Application of a microfluidic chip-based 3D co-culture to test drug sensitivity for individualized treatment of lung cancer. Biomaterials34 (16), 4109–4117. 10.1016/j.biomaterials.2013.02.045
75
XuZ.LiE.GuoZ.YuR.HaoH.XuY.et al (2016). Design and construction of a Multi-Organ microfluidic chip mimicking the in vivo microenvironment of lung cancer metastasis. ACS Appl. Mater Interfaces8 (39), 25840–25847. 10.1021/acsami.6b08746
76
YangX.LiK.ZhangX.LiuC.GuoB.WenW.et al (2018). Nanofiber membrane supported lung-on-a-chip microdevice for anti-cancer drug testing. Lab. Chip18 (3), 486–495. 10.1039/c7lc01224a
77
YingL.ZhuZ.XuZ.HeT.LiE.GuoZ.et al (2015). Cancer associated Fibroblast-Derived hepatocyte growth factor inhibits the Paclitaxel-Induced apoptosis of lung cancer a549 cells by Up-Regulating the PI3K/Akt and GRP78 signaling on a microfluidic platform. PLoS One10 (6), e0129593. 10.1371/journal.pone.0129593
78
ZamprognoP.WuthrichS.AchenbachS.ThomaG.StuckiJ. D.HobiN.et al (2021). Second-generation lung-on-a-chip with an array of stretchable alveoli made with a biological membrane. Commun. Biol.4 (1), 168. 10.1038/s42003-021-01695-0
79
ZhengL.WangB.SunY.DaiB.FuY.ZhangY.et al (2021). An Oxygen-Concentration-Controllable multiorgan microfluidic platform for studying Hypoxia-Induced lung Cancer-Liver metastasis and screening drugs. ACS Sens.6 (3), 823–832. 10.1021/acssensors.0c01846
80
ZimmermannB. (1987). Lung organoid culture. Differentiation36 (1), 86–109. 10.1111/j.1432-0436.1987.tb00183.x
81
ZuchowskaA.JastrzebskaE.ChudyM.DybkoA.BrzozkaZ. (2017). 3D lung spheroid cultures for evaluation of photodynamic therapy (PDT) procedures in microfluidic Lab-on-a-Chip system. Anal. Chim. Acta990, 110–120. 10.1016/j.aca.2017.07.009
Summary
Keywords
3D culture system, lung organoid, lung-on-a-chip, lung cancer, drug evaluation
Citation
Zhu L, Zhang J, Guo Q, Kuang J, Li D, Wu M, Mo Y, Zhang T, Gao X and Tan J (2023) Advanced lung organoids and lung-on-a-chip for cancer research and drug evaluation: a review. Front. Bioeng. Biotechnol. 11:1299033. doi: 10.3389/fbioe.2023.1299033
Received
22 September 2023
Accepted
26 October 2023
Published
07 November 2023
Volume
11 - 2023
Edited by
Zhaobin Guo, Shanghai University of Traditional Chinese Medicine, China
Reviewed by
Ke Hu, Nanjing Medical University, China
Min Tang, Shanghai University of Traditional Chinese Medicine, China
Updates
Copyright
© 2023 Zhu, Zhang, Guo, Kuang, Li, Wu, Mo, Zhang, Gao and Tan.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jianfeng Tan, tjf_601@smu.edu.cn; Xinghua Gao, gaoxinghua@t.shu.edu.cn
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.